Deciphera Pharmaceuticals (DCPH)

Company Profile

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.

Company profile

Ticker

DCPH

Exchange

NASDAQ

Website

www.deciphera.com

CEO

Steven Hoerter

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

Deciphera Pharmaceuticals, LLC

SEC CIK

0001654151

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Deciphera Pharmaceuticals, LLC • Deciphera Pharmaceuticals Securities Corporation ...

DCPH stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$22.25

Low target

$9.00

High target

$30.00

Latest filings (excl ownership)

View all

8-K

Entry into a Material Definitive Agreement

20 Jan 23

424B5

Prospectus supplement for primary offering

Prospectus supplement for primary offering

18 Jan 23

8-K

Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company

3 Nov 22

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results

3 Nov 22

8-K

Regulation FD Disclosure

12 Sep 22

EFFECT

Notice of effectiveness

11 Aug 22

CORRESP

Correspondence with SEC

8 Aug 22

Transcripts

View all

DCPH

Earnings call transcript

2022 Q2

7 Aug 22

DCPH

Earnings call transcript

2022 Q1

8 May 22

DCPH

Earnings call transcript

2021 Q4

9 Feb 22

DCPH

Earnings call transcript

2021 Q3

3 Nov 21

DCPH

Earnings call transcript

2021 Q2

4 Aug 21

DCPH

Earnings call transcript

2021 Q1

10 May 21

DCPH

Earnings call transcript

2020 Q4

10 Feb 21

DCPH

Earnings call transcript

2020 Q3

8 Nov 20

DCPH

Earnings call transcript

2020 Q2

5 Aug 20

DCPH

Earnings call transcript

2020 Q1

10 May 20

Latest ownership filings

View all

Change in insider ownership

24 Jan 23

Franklin Stuart Friedman

Financial summary

Financial statements Chart DCPH financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	82.54 mm	82.54 mm	82.54 mm	82.54 mm	82.54 mm	82.54 mm
Cash burn (monthly)	9.05 mm	(no burn)	14.96 mm	18.66 mm	6.94 mm	15.41 mm
Cash used (since last report)	37.47 mm	n/a	61.91 mm	77.24 mm	28.73 mm	63.76 mm
Cash remaining	45.07 mm	n/a	20.63 mm	5.30 mm	53.81 mm	18.78 mm
Runway (months of cash)	5.0	n/a	1.4	0.3	7.8	1.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

DCPH institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	151	131	+15.3%
Opened positions	34	22	+54.5%
Closed positions	14	17	-17.6%
Increased positions	59	46	+28.3%
Reduced positions	33	38	-13.2%

13F shares	Current	Prev Q	Change
Total value	936.75 mm	723.56 mm	+29.5%
Total shares	69.74 mm	71.92 mm	-3.0%
Total puts	0.00	0.00
Total calls	408.70 k	350.60 k	+16.6%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Brightstar Associates	16.57 mm	$0.00	0.0%
Flynn James E	5.58 mm	$54.52 mm	0.0%
BLK Blackrock	5.21 mm	$96.42 mm	-5.7%
Vanguard	4.79 mm	$88.71 mm	+9.2%
Armistice Capital	4.77 mm	$88.21 mm	-11.7%
GS Goldman Sachs	3.77 mm	$69.69 mm	+2.8%
Redmile	2.97 mm	$55.00 mm	+107.8%
Deerfield Management	2.49 mm	$46.09 mm	-60.1%
SVLSF Vi	1.72 mm	$33.86 mm	0.0%
Assenagon Asset Management	1.40 mm	$25.97 mm	+99.2%

Largest transactions	Shares	Bought/sold	Change
STT State Street	0.00	-3.93 mm	EXIT
Deerfield Management	2.49 mm	-3.76 mm	-60.1%
Redmile	2.97 mm	+1.54 mm	+107.8%
Assenagon Asset Management	1.40 mm	+699.07 k	+99.2%
FHI Federated Hermes	248.17 k	-689.15 k	-73.5%
Nuveen Asset Management	813.65 k	+669.85 k	+465.8%
Armistice Capital	4.77 mm	-632.00 k	-11.7%
D. E. Shaw & Co.	790.41 k	+623.53 k	+373.6%
T. Rowe Price	716.76 k	+569.96 k	+388.3%
Jefferies	188.52 k	-502.51 k	-72.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DCPH insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
24 Jan 23	Brightstar Associates	Common Stock	Buy	Acquire P	No	No	18	1,666,666	30.00 mm	19,718,014
17 Jan 23	Friedman Franklin Stuart	Stock Option Common Stock	Grant	Acquire A	No	No	15.2952	3,269	50.00 k	3,269
17 Jan 23	Flynn Daniel Lee	Common Stock	Sell	Dispose S	No	No	21.2413	2,403	51.04 k	43,695
17 Jan 23	Allen Patricia L	Stock Option Common Stock	Grant	Acquire A	No	No	15.2952	3,269	50.00 k	3,269
17 Jan 23	Daniel C. Martin	Common Stock	Sell	Dispose S	No	No	21.2413	1,603	34.05 k	48,389